RE:RE:RE:RE:Just Listened to AGM Kulkarni Presentation NeilPaert74 wrote: enriquesuave wrote: Hemp, Maybe all 3 who were CR at 90 days are still CR at 6 months. We don't yet know about 3 rd 90 day CR patient. So it is looking very good so far for those who are initially CR. IMO
Hempdoc wrote:
enriquesuave wrote: Both Dr Kulkarni and Dr Jewett sounded very optimistic for this technology. Dr Jewett mentioned us very well placed competitively compared to other treatments and also praised the safety aspect versus other cancer treatments. Dr Kulkarni mentioned that 2 of the patients who wer CR at 90 days were still CR at 6 months mark. They must of have received 2nd treatment as well.IMO. They still don't have 6 months data for all patients and now that treatment is optimized, we should see even better as seemed to be the impression both doctors had. So out of 15 patients for PH1 and PH2 who have received high dose, 5 are CR or 33%. As Dr Jewett mentioned maximum bladder volume will be now used in optimization, so no more undertreated patients hopefully. We are lucky to have 25% CR on these 12 patients given under treatment by an average of 75% which shows the treatment works extremely well when simply using the right protocol. Dr Jewett also mentioned that the other investigators from the other sites were very excited about this technology. Patients are being enrolled in all 4 sites let's hope we can treat 12-15 in next 5-6 months. 5 US sites expected to onboard Q4 as well as one more Canadian site. All will be using Optimized procedure a lesson well learnt by now. All IMO
Thanks for sharing Enrique...
Re: "
Dr Kulkarni mentioned that 2 of the patients who wer CR at 90 days were still CR at 6 months mark."
There were 3 patients who had CR at 90 days, so 2/3 of these particular under-dosed patients remained CR at 6 months...not bad at all.
Re: "So out of 15 patients for PH1 and PH2 who have received high dose, 5 are CR or 33%."
5/15 or 33% with a CR is pretty good, but when only 2/15 actually receive the proper/therapeutic dose....not bad at all : )
Doc, it should be 4 of 15, phase 1 patients 5&6 and the 2 from phase 2 that were given proper dose. Is that right? the final tally? Your math still looking good to me either way. ;-)
Hi NeilPaert....
Per the July 30 NR:
Summary:
The total of these Study II variances (Study Drug Volume, Study Device Volume and Study Device Treatment Time) have led to all 12 patients being undertreated by the Study Treatment from between 30.9% and 154.3%.